Clinical Study Of Shengjiang Power In Treating Acute Stage Of Ischemic Stroke(Syndrome Of Excessive Fu-viscera Caused By Phlegm-heat) And Its Influence On Inflammatory Reaction

Objectives:To observe the clinical efficacy of Shengjiang powder in the treatment of acute stage of ischemic stroke(phlegm-heat fu-organ syndrome)and its effect on acute stroke inflammatory response.In order to provide more clinical and theoretical basis for the treatment of acute stage of ischemic stroke(phlegm-heat fu-organs)by Shengshanshan,we hope to use TCM syndrome differentiation treatment method to provide a new way of treatment and medication for acute ischemic apoplexy.Methods:A total of 67 patients in the Encephalopathy Center of the first affiliated Hospital of Anhui University of traditional Chinese Medicine were randomly divided into control group,treatment group and control group.In the treatment group,the general baseline data(age,sex,course of disease,etc.)were not significantly different between the two groups on the basis of the comprehensive intervention of the western medicine combined with the oral administration of the traditional Chinese medicine Shengjiang powderObservation of serum hs-CRP,Hcy,TNF-? and IL-6 in two groups after continuous treatment for 2 weeks.Changes of NIHSS score(National institutes of health stroke scale,NIHSS),DCI score(Disease class integral,DCI)in two groups of Western Medicine Clinical efficacy and Stroke Syndrome Therapeutic effect improvement.In order to evaluate the clinical efficacy of clinical effect of Shengjiang powder on patients with phlegm-heat fu-organ syndrome in the middle stage of ischemic stroke and effect of Shengjiang powder on inflammatory response in Acute stage of Ischemic Stroke.Results:(1)Clinical efficacy comparison:(1)The NIHSS scores of the two groups before and after treatment were significantly higher than those of the control group(P<0.01).Experimental datas show that after treatment,the level of neurologic impairment in both groups is better than that on admission.Comparison of NIHSS scores between two groups after treatment(P<0.01).The results showed that the NIHSS score of the treatment group decreased more significantly than that of the control group after 2 weeks of treatment.The improvement of neurologic function in the treatment group was significantly better than that in the control group.(2)After treatment,the total effective rate was 96.67% in the treatment group and 83.33% in the control group(P<0.05).There was a significant difference in the clinical efficacy between the two groups.The effective rate in the treatment group was higher than that in the control group.It is suggested that the therapeutic effect of treatment group is better than that of control group.(2)Comparison of apoplexy score and curative effect of apoplexy:(1)the scores of stroke disease before and after treatment in the treatment group and control group were all lower than those before treatment(P<0.01),and there was significant difference between the two groups(P<0.01).The results of the experiment showed that the scores of stroke patients in both groups were improved compared with those before.After two weeks of continuous treatment,the scores of stroke patients in the two groups were compared(P<0.05).There was no significant difference between the two groups.The treatment group was superior to the control group in the improvement of TCM syndrome of apoplexy after treatment.(2)Comparison of the curative effect of apoplexy: the total effective rate was 96.67% in the treatment group and 90% in the control group after treatment,and the difference was statistically significant between the two groups(P<0.05).The experimental data show that the treatment group is better than the control group in improving the percentage of curative effect of stroke,indicating that the treatment group is better than the control group in the treatment of apoplexy.(3)Comparison of serum inflammatory indexes:(1)Intra-group comparison: the levels of serum hs-CRP in the two groups were compared before and after treatment(P<0.01);The levels of serum Hcy in the two groups were compared before and after treatment(P<0.01).Comparison of serum TNF-? concentration before and after treatment between the two groups(P<0.01)and serum IL-6 concentration before and after treatment(P<0.01).The levels of serum hs-CRP,Hcy,TNF-? and IL-6 in the two groups before and after treatment were statistically significant(P<0.01).It was proved that the serum hs-CRP,Hcy,TNF-?and IL-6 levels in the treatment group and the control group after 2 weeks treatment were statistically significant(P<0.01).The levels of hsCRP,Hcy,TNF-? and IL-6 were significantly lower than those at admission.(2)Comparison between the two groups: the serum hs-CRP concentration of the two groups was compared after treatment(P<0.01),and the serum Hcy concentration of the two groups was compared after treatment(P<0.01).The levels of serum TNF-? in the two groups were compared after treatment(P<0.01),and the levels of serum IL-6 in the two groups were compared after treatment(P< 0.01).The experimental data were statistically significant between the control group and the treatment group after 2 weeks of treatment(P<0.01).The results showed that the serum hs-CRP,Hcy,TNF-?and IL-6 of the treatment group after 2 weeks of continuous treatment was significantly higher than that of the control group(P<0.01).The decrease of hs-CRP,Hcy,TNF-?and IL-6 concentration was better than that of control group.(4)Safety evaluation:There were no significant adverse reactions in both groups during the study period.Comparison of blood routine,urine routine,stool routine,coagulation routine grade liver and kidney function between the two groups before and after treatment(P>0.05).It is suggested that Shengjiang powder is safe in treating acute ischemic stroke patients.Conclusion:(1)Shengjiang powder has a certain clinical effect in treating patients with phlegm-heat fu-organ syndrome in acute stage of ischemic stroke,which can improve the nerve function defect and help the recovery of TCM syndrome,and the improvement degree of symptoms in the treatment group is better than that in the control group after 2 weeks of treatment;Shengjiang powder can decrease the abnormal increase of serum hs-CRP,Hcy,TNF-? and IL-6 concentration in acute stage of ischemic stroke.(2)In the course of this study,no obvious toxicity and side effects related to experimental drugs were found,which provided theoretical and clinical evidence for the treatment of phlegm-heat fu-organs in acute ischemic stroke patients,which indicated that Shengjiang powder was safe and effective in clinical use.It is worth popularizing and providing theoretical and clinical support for further study on the treatment of apoplexy in acute phase by traditional Chinese medicine.